Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease

European Journal of Clinical Investigation

Volumn 40, Issue 4, 2010, Pages 294-300

  Lorenzen, Johan ^a   Krämer, Robert ^a   Kliem, Volker ^b   Bode Boeger, Stefanie M ^c   Veldink, Hendrik ^a   Haller, Hermann ^a   Fliser, Danilo ^d   Kielstein, Jan T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Nephrological Centre Lower Saxony   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

ADMA; Atherosclerosis; Osteopontin; Renal function; SDMA; Vascular calcification

Indexed keywords

ANTIHYPERTENSIVE AGENT; CREATININE; DIMETHYLARGININASE; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; OSTEOPONTIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MARKER; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INULIN CLEARANCE; KIDNEY DONOR; KIDNEY FUNCTION; PRIORITY JOURNAL; UNINEPHRECTOMY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MIDDLE AGED; OSTEOPONTIN; RISK FACTORS;

EID: 77949720837     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02271.x     Document Type: Article

References (38)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P et al. Prevalence of chronic kidney disease in the United States. JAMA 2007 298 : 2038 2047.
2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003 108 : 2154 2169.
3. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006 16 : 79 87.
4. Rangaswami H, Bulbule A, Kundu GC. JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation. J Biol Chem 2005 280 : 19381 19392.
5. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem 2004 279 : 38921 38935.
6. O'Regan A, Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 2000 81 : 373 390.
7. 1 to osteopontin. Matrix Biol 2005 24 : 418 427.
8. 1 integrin-osteopontin interaction. Exp Cell Res 2000 258 : 342 351.
9. Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, Hirokawa K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 1993 92 : 2814 2820.
10. Giachelli CM, Base N, Almeida MM, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993 92 : 1686 1696.
11. Isoda K, Kamezawa Y, Ayaori M, Kusuhara M, Tada N, Ohsuzu F. Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions. Circulation 2003 107 : 679 681.
12. Kurata M, Okura T, Watanabe S, Fukuoka T, Higaki J. Osteopontin and carotid atherosclerosis in patients with essential hypertension. Clin Sci 2006 111 : 319 324.
13. Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003 170 : 333 337.
14. Kato R, Momiyama Y, Ohmori R, Tanaka N, Taniguchi H, Arakawa K et al. High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. Arterioscler Thromb Vasc Biol 2006 26 : e1 2.
15. Speer MY, McKee MD, Guldberg RE, Liaw L, Yang HY, Tung E et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 2002 196 : 1047 1055.
16. Kielstein JT, Böger RH, Bode-Böger SM, Frölich JC, Haller H, Ritz E et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002 13 : 170 176.
17. Martens-Lobenhoffer J, Bode-Böger SM. Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 2006 52 : 488 493.
18. Kuehnle HF, von DK, Schmidt FH. Fully enzymatic inulin determination in small volume samples without deproteinization. Nephron 1992 62 : 104 107.
19. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function - a meta-analysis. Nephrol Dial Transplant 2006 21 : 2446 2451.
20. Kielstein JT, Salpeter SR, Buckley NS, Cooke JP, Fliser D. Two cardiovascular risk factors in one? Homocysteine and its relation to glomerular filtration rate. A meta-analysis of 41 studies with 27,000 participants Kidney Blood Press Res 2008 31 : 259 267.
21. Kleinman JG, Beshensky A, Worcester EM, Brown D. Expression of osteopontin, a urinary inhibitor of stone mineral crystal growth, in rat kidney. Kidney Int 1995 47 : 1585 1596.
22. Ophascharoensuk V, Giachelli CM, Gordon K, Hughes J, Pichler R, Brown P et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 1999 56 : 571 580.
23. Persy VP, Verstrepen WA, Ysebaert DK, De Greef KE, De Broe ME. Differences in osteopontin up-regulation between proximal and distal tubules after renal ischemia/reperfusion. Kidney Int 1999 56 : 601 611.
24. Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, Nicholas SB. Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 2009 76 : 32 43.
25. Jackle I, Gunther W, von Gise H, Alt JM, Bohle A, Stolte H. Kidney function and protein excretion in relation to pathomorphology of glomerular diseases. Contrib Nephrol 1988 68 : 128 135.
26. Nikolic-Paterson DJ, Atkins RC. The role of macrophages in glomerulonephritis. Nephrol Dial Transplant 2001 16 (Suppl. 5 3 7.
27. Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, Coen E et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006 27 : 802 807.
28. Brosius FC III., Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA et al. American Heart Association Kidney and Cardiovascular Disease Council; Council on High Blood Pressure Research; Council on Cardiovascular Disease in the Young; Council on Epidemiology and Prevention; Quality of Care and Outcomes Research Interdisciplinary Working Group: Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation 2006 114 : 1083 1087.
29. Kilic T, Oner G, Ural E, Yumuk Z, Sahin T, Bildirici U et al. Comparison of the long-term prognostic value of Cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. Atherosclerosis 2009 207 : 552 558.
30. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl 2003 S105 10.
31. Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009 119 : 1592 1600.
32. Böger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality - an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res. 2009 60 : 481 487.
33. Giachelli C, Bae N, Lombardi D, Majesky M, Schwartz S. Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR). Biochem Biophys Res Commun 1991 177 : 867 873.
34. Gadeau AP, Campan M, Millet D, Candresse T, Desgranges C. Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler Thromb 1993 13 : 120 125.
35. Ihara H, Denhardt DT, Furuya K, Yamashita T, Muguruma Y, Tsuji K et al. Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J Biol Chem 2001 276 : 13065 13071.
36. Steitz SA, Speer MY, McKee MD, Liaw L, Almeida M, Yang H et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 2002 161 : 2035 2046.
37. Wada T, McKee MD, Steitz S, Giachelli CM. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999 84 : 166 178.
38. 3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem 1991 266 : 20369 20374.